Send me real-time posts from this site at my email
Motley Fool

Here's Why Stealth BioTherapeutics Rocketed Higher Today

What happened

Shares of Stealth BioTherapeutics (NASDAQ: MITO) are up 9.8% at 1:11 p.m. EDT, having been up as much as 35%, following the announcement that the biotech gave Alexion Pharmaceuticals (NASDAQ: ALXN) an option to license elamipretide, Stealth's late-stage drug candidate for mitochondrial diseases.

So what

Stealth BioTherapeutics will get $30 million from Alexion Pharmaceuticals, which includes an equity investment, option fee, and development funding. Alexion has the option to enact the license after seeing the results from an ongoing phase 3 clinical trial testing elamipretide in patients with a genetic mitochondrial disease called primary mitochondrial myopathy (PMM).

If Alexion chooses to license the drug, Stealth is eligible for an undisclosed option exercise fee, additional equity investment, development funding, and regulatory and commercial milestone payments. The companies will co-develop the drug for PMM, Barth syndrome, and Leber's hereditary optic neuropathy and share equal responsibilities for marketing the drug in the U.S. Outside the U.S., Alexion will take the lead.

Image source: Getty Images.

Now what

A partnership with Alexion is certainly good news; it's an endorsement in elamipretide's potential and provides much needed cash to Stealth for the launch of elamipretide and the development of the rest of its pipeline. But keep in mind, it's an option deal, so Alexion hasn't quite gone all-in on elamipretide yet.

Unfortunately, it's a little hard for biotech investors to really value this deal because Stealth didn't provide any details on the deal terms other than the $30 million upfront payment, which is certainly a small amount to accept for giving up half of the rights to a drug. There's potential for more, of course; yet without knowing how much Stealth will get if Alexion exercises its option, it's impossible to say if Stealth has gotten a good deal and probably explains the reason for today's pullback in the stock price after the initial jubilation wore off.

10 stocks we like better than Stealth BioTherapeutics

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Stealth BioTherapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 1, 2019

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue